OBSTETRICS

Biomarkers used in the early prediction of gestational diabetes

 Biomarkeri utilizaţi în predicţia timpurie a diabetului gestaţional

First published: 30 mai 2024

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/Gine.44.2.2024.9657

Abstract

Objectives. The evaluation of maternal biomarkers that can guide us towards an early diagnosis of gestational dia­betes, as early as the first trimester of pregnancy, for a better management and to reduce potential adverse ef­fects of gestational diabetes on pregnancy and pregnant wo­men. Methodology. This article reviews research in the spe­cia­lized literature and aims to highlight how biomarkers, such as fasting glucose, HOMA score, glycated hemoglobin and PAPP-A, can constitute a set of parameters for screening ges­ta­tional diabetes as early as the first trimester of preg­nancy. Results. Women who developed gestational diabetes ex­hi­bi­ted higher values of biomarkers compared to patients un­af­fec­ted by this metabolic imbalance. Diagnosing ges­ta­tio­nal diabetes in the first trimester of pregnancy re­quires correlating multiple biological markers. Most stu­dies suggest that none of the markers used alone have a suf­fi­ciently high predictive value for screening gestational dia­betes in the first trimester. However, their correlation can quan­tify the risk of developing this condition and provide a clinical clue in routine practice.
 

Keywords
biomarker, insulin, HOMA, glycated hemo­globin, OGTT, PAPP-A, gestational diabetes, ADA criteria, ACOG criteria

Rezumat

Obiective. Evaluarea biomarkerilor materni care ne pot ghi­da către un diagnostic precoce al diabetului gestaţional, încă din primul trimestru de sarcină, pentru un management mai bun şi pentru reducerea potenţialelor efecte adverse ale dia­be­tu­lui gestaţional asupra sarcinii şi femeilor însărcinate. Me­to­do­lo­gie. Acest articol trece în revistă cercetările din li­te­ra­tura de specialitate şi îşi propune să evidenţieze modul în care biomarkeri precum glicemia à jeun, scorul HOMA, he­mo­glo­bina glicată şi PAPP-A pot constitui un set de pa­ra­metri pentru scre­enin­gul diabetului gestaţional încă din primul tri­mes­tru de sar­cină. Rezultate. Femeile care au dez­vol­tat diabet gestaţional au prezentat valori mai mari ale bio­­mar­ke­rilor în comparaţie cu pa­cien­ţii neafectaţi de acest dez­echi­li­bru metabolic. Diag­nos­ti­cul diabetului gestaţional în primul trimestru de sarcină ne­ce­si­tă co­re­la­rea mai multor markeri biologici. Cele mai multe stu­dii su­ge­rea­ză că niciunul dintre markerii utilizaţi singuri nu are o va­loa­re predictivă suficient de mare pentru screeningul dia­be­tu­lui gestaţional în primul trimestru. Cu toate acestea, corelarea lor poate cuan­ti­fi­ca riscul de a dezvolta această afecţiune şi poa­te oferi un in­di­ciu clinic în practica de rutină.
 

Introduction

With the increasing incidence of obesity in the general population, the incidence of gestational diabetes mellitus (GDM) has followed a similar upward trend, being associated with multiple perinatal complications. The history of medicine reveals the recognition of gestational diabetes as a pregnancy complication as early as 1873(1). In 1910, a differentiation was proposed between patients who had glycosuria before pregnancy and those who developed glycosuria during pregnancy. From these early cases, the distinction between preexisting diabetes and gestational diabetes was acknowledged. The first studies on carbohydrate metabolism during pregnancy were initiated in 1946(2).

Pregnancy represents a diabetogenic state, and insulin resistance often increases during the third trimester. Gestational diabetes occurs when pancreatic function does not compensate for insulin resistance. It was believed that diabetogenic hormones (growth hormone, corticotropin-releasing hormone, human placental lactogen, and progesterone) secreted by the placenta induce this pathology. Placental growth hormone increases insulin resistance to facilitate fetal nutrition. Additionally, human placental lactogen and prolactin stimulate the mother’s appetite by increasing resistance to leptin and promote the proliferation of maternal pancreatic beta cells, leading to insulin production to defend against the development of gestational diabetes(3).

Fetal exposure to an abnormal intrauterine environment, such as a pregnancy with GDM, can impact fetal programming, increasing the risk of developing the metabolic syndrome characterized by diabetes, obesity and, importantly, hypertension throughout life(4). This is why numerous efforts have been made to break this vicious cycle.

Currently, the universally accepted screening for gestational diabetes is the glucose tolerance test performed between 24 and 28 weeks of pregnancy.

Materials and method

This article aims to highlight the possibility of using alternative biomarkers for the screening and early detection of gestational diabetes mellitus as early as the first trimester of pregnancy. The goal is to detect changes in a clinically silent phase of GDM and prevent subsequent complications.

The inclusion criteria were:

  • a single fetus pregnancy
  • gestational age less than 14 weeks confirmed by ultrasound
  • the informed consent from the patient.

The exclusion criteria were:

  • a history of diabetes or insulin resistance (preconception history of altered insulin levels or carbohydrate intolerance in a glucose challenge test)
  • use of metformin one month before pregnancy
  • fasting blood glucose >105 mg/dL or
  • basal blood glucose >200 mg/dL in the first trimester
  • alcohol or drug abuse
  • active mental illness.

In the studies, serum concentrations of insulin(5), BMI, PAPP-A, cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL) and very-low-density lipo­proteins (VLDL) were determined according to the manufacturer’s instructions. Homeostatic Model Assessment (HOMA) was calculated using the Matthews formula [insulin (µU/mL) × glucose (mmol/L)/22.5]. Blood glucose concentration and total blood glycosylated hemoglobin were quantified.

Pregnant women at high risk of gestational diabetes(6-14)

The pregnant women with one of the following characteristics seem to have a higher risk of developing GDM. The risk varies depending on these characteristics, and it is additive when multiple risk factors are present.

  • Personal history:
  • GDM in a previous pregnancy (associated with a 40% recurrence risk)
  • Altered glucose tolerance
  • HbA1c ≥5.7%
  • Elevated fasting blood glucose.
  • Family history of diabetes, especially in a first-degree relative.
  • Preconceptional Body Mass Index (BMI) ≥30 kg/m2 or significant weight gain at the beginning of adulthood or between pregnancies, or excessive weight gain in the first 18 to 24 weeks of pregnancy.
  • Medical conditions associated with the development of diabetes mellitus – e.g., polycystic ovary syndrome (PCOS).
  • Advanced maternal age (≥35 years old).
  • Member of an ethnic group with a high prevalence of type 2 diabetes such as: Hispanic Americans; American Indians, Alaska Natives, or Native Hawaiians; South Asian or East Asian, Pacific Islanders.
  • Previous birth of a child ≥4000 g.

Unrecognized and untreated hyperglycemia in the early stages of pregnancy is important because it is associated with an increased risk of spontaneous abortion and congenital anomalies. Additionally, a number of other unrecognized maternal comorbidities, such as nephropathy or retinopathy, can have serious maternal and obstetric consequences. If these patients are identified early in pregnancy, they could benefit from diagnostic and therapeutic interventions routinely provided to pregnant women with preexisting (pregestational) diabetes.

Early pregnancy screening (universal screening through HbA1c)

Checking the HbA1c level as part of routine prenatal tests can detect gestational diabetes mellitus even from the first prenatal visit.

Other approaches in early pregnancy screening

Targeted screening of individuals at high risk. The International Association of Diabetes and Pregnancy Study Groups (IADPSG)(18), the American Diabetes Association (ADA)(15), and The American College of Obstetricians and Gynecologists (ACOG)(16) – suggest directing early pregnancy screening towards individuals at high risk of undiagnosed type 2 diabetes. However, ADA also suggests physicians consider testing all individuals for undetected diabetes at the first prenatal visit (or before conception). In contrast, a recommendation from the U.S. Preventive Services Task Force (USPSTF) concluded that the available evidence is insufficient to assess the balance of benefits and risks of screening asymptomatic pregnant individuals for glucose intolerance before the 24th week of gestation(5).

ADA and ACOG define patients at high risk for type 2 diabetes based on:

GDM in a previous pregnancy.
Preconceptional BMI ≥25 kg/m2 (≥23 kg/m2 for Asian-Americans), plus one or more of the following:
  • first-degree relatives with diabetes
  • high-risk race/ethnicity (e.g., African American, Latino, American Indian, Asian American, Pacific Islander)
  • history of cardiovascular diseases
  • hypertension (≥130/80 mmHg before pregnancy) or treatment for hypertension
  • HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or triglyceride level >250 mg/dL (2.82 mmol/L)
  • polycystic ovary syndrome (PCOS)
  • physical inactivity
  • other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans).

 

  • Glycated hemoglobin ≥5.7% (39 mmol/mol), impaired glucose tolerance (glucose level at two hours between 140 and 199 mg/dL), or modified fasting glucose (glucose level between 100 and 125 mg/dL) in a pregestational 75-gram oral glucose tolerance test (OGTT).
  • HIV infection or exposure to high-risk medications or a history of pancreatitis.
  • Age ≥35 years old.

In a randomized clinical study, screening for diabetes during pregnancy due to the presence of obesity (BMI ≥30 kg/m2) did not demonstrate a reduction in potential adverse effects (e.g., macrosomia, primary caesarean section, pregnancy-induced hypertension, shoulder dystocia, neonatal hyperbilirubinemia, or hypoglycemia)(19).

Directing screening toward symptomatic patients is not useful because many patients are asymptomatic or have unrecognized mild symptoms. However, those with random blood glucose values ≥200 mg/dL (11.1 mmol/L) may experience symptoms of hyperglycemia (e.g., polydipsia, polyuria, weight loss, blurred vision).

The choice of screening test

No approach has been validated for diagnosing diabetes in the first or second trimester of pregnancy. Clinical practice varies depending on the institution and clinician preference. Screening may involve a single A1C, a single fasting blood glucose, a 75-gram oral glucose tolerance test (OGTT) for two hours, or a two-step test (a 50-gram OGTT for one hour followed by a 100-gram OGTT for three hours if the 50-gram OGTT is positive).

If a two-step test is used, we will present the ACOG criteria for diabetes. These criteria are the same as those used for diagnosing gestational diabetes mellitus (GDM) later in pregnancy(20).

Management of patients after an altered early pregnancy OGTT

The benefit of treating a patient whose early pregnancy oral glucose tolerance test meets the ADA criteria for gestational diabetes has not been established. A randomized clinical study, involving over 800 pregnant participants with an abnormal OGTT at the two-hour mark with 75 grams of oral glucose solution before 20 weeks of gestation, compared immediate treatment with retesting between 24 and 28 weeks and initiating treatment for abnormal results.

The immediate treatment of patients who meet the diagnostic criteria for GDM in the early stages of pregnancy did not lead to a clear or significant reduction in births of large-for-gestational-age infants, pregnancy-induced hypertension, or other adverse effects(5).

Glucose tolerance test procedure in pregnancy
Glucose tolerance test procedure in pregnancy
Diagnostic values for gestational diabetes
Diagnostic values for gestational diabetes



HOMA+BMI

Ozcimen et al. reported that gestational diabetes can be predicted in the first trimester if the HOMA-IR score is higher 2.60(23). The predictability for the development of gestational diabetes increased when BMI, waist-to-hip ratio, and weight gain in the first trimester were added and combined with HOMA-IR. Controlling weight gain reduces the incidence of gestational diabetes in pregnant women with elevated BMI and HOMA-IR at the first prenatal visit. In this study, gestational diabetes was predicted in the first trimester with a sensitivity of 80% and a specificity of 58% in pregnant women with a BMI>25.95 kg/m2 at the first prenatal visit, consistent with other studies(3).

Catalano et al. demonstrated the progressive deterioration of insulin sensitivity in obese women (47%) and in women with normal weight (56%) during the third trimester. Before these gestational weeks, hyperinsulinemia as an independent state of pregnancy may indicate a risk of gestational diabetes(24). Insulin resistance cannot be measured through a standardized test. Many studies have used HOMA-IR or HOMA, based on the glucose-insulin ratio(25,26). In conclusion, HOMA-IR and the insulin sensitivity check index have been recommended, but there is no universally accepted threshold for HOMA-IR. We determined the predictability of gestational diabetes with a sensitivity of 90% and a specificity of 61% through ROC analysis in patients whose HOMA-IR scores were higher than 2.08 in the first trimester(3).

Although the studies had some limitations, they showed that gestational diabetes can be predicted using first-trimester data, such as elevated BMI and HOMA-IR values. We can conclude that gestational diabetes can be detected in the first trimester using anthropometric measurements and HOMA-IR. To date, this study is the first to suggest threshold values for HOMA-IR, BMI, and weight gain in the first trimester for gestational diabetes. The main conclusion of this study is that pregnant women with a BMI>25.95 kg/m2, HOMA-IR>2.08, and weight gain above 4.7 kg are considered at high risk for gestational diabetes(27).

PAPP-A

Pregnancy-associated plasma protein-A (PAPP-A) is a high molecular weight metalloproteinase which, in low quantities, is associated with the presence of fetal Down syndrome. However, its performance as a screening marker gradually decreases with the advancement of gestational age from 9 to 13 weeks(28). Studies also indicate that low PAPP-A levels may suggest an increased risk for spontaneous abortion, low birth weight, intrauterine growth restriction, preeclampsia, premature rupture of membranes, or placental abruption(29,30).

Recent observations have noted that the presence of low levels of pregnancy-associated plasma protein-A in the first trimester is correlated with the later development of gestational diabetes(31).

Study results demonstrate a connection between serum PAPP-A levels in the first trimester and gestatio­nal diabetes, but with moderately predictive outcomes. PAPP-A, produced in the placenta and decidua, acts as a pro­te­ase controlling insulin-like growth factor (IGF) in re­la­tion to insulin-like growth factor-binding protein (IGFBP). PAPP-A breaks down IGFBP, thus low PAPP-A levels lead to an increased amount of IGFBP, causing a decrease in IGF. Insulin-like growth factor promotes the absorption of ami­no acids and glucose in the trophoblast and acts as an au­to­crine and paracrine regulator of trophoblastic in­va­sion into the decidua. Therefore, low PAPP-A levels may worsen placental conditions and contribute to the oc­cur­rence of adverse effects. Additionally, low IGF levels promote increased circulating insulin, insulin resistance, and abnormal glucose clearance(32).

A meta-analysis of over 300 specialized articles using PAPP-A as a biomarker for predicting gestational diabetes revealed an average sensitivity of 55% (53-58%) and a specificity of 90% (89-90%). The conclusion of this meta-analysis was that low PAPP-A in the first trimester of pregnancy has low predictive accuracy for gestational diabetes. However, this variable can be useful in combination with other tests. Gestational diabetes is a silent condition with few specific symptoms, making PAPP-A levels a potential clue in clinical practice(32).

Conclusions

Although testing for gestational diabetes in weeks 24-28 of pregnancy remains a cornerstone for diagnosing this condition, as we have seen before, studies indicate that an earlier diagnosis can prevent potential complications for both the fetus and the mother.

Diagnosing gestational diabetes in the first trimester of pregnancy requires correlating several biological markers. As mentioned earlier, most studies attest that none of the markers used individually has a predictive value high enough for first-trimester gestational diabetes screening. However, their correlation can help quantify the risk of developing this condition and provide a clinical clue in routine practice.

Corresponding author: Gabriela Ionescu
E-mail: gabriela.ionescu@drd.umfcd.ro
 

Conflict of interest: none declared.

financial support: none declared.

This work is permanently accessible online free of charge and published under the CC-BY licence.  

Bibliografie

  1. Duncan JM. Case of pregnancy and labour complicated with diabetes mellitus. Edinb Med J. 1873;18(8):696-8.
  2. Hurwitz D, Jensen D. Carbohydrate metabolism in normal pregnancy. New Engl J Med. 1946;234(10):327-9.
  3. Alptekin H, Çizmecioğlu A, Işık H, Cengiz T, Yildiz M, Iyisoy MS. Predicting gestational diabetes mellitus during the first trimester using anthropometric measurements and HOMA-IR. J Endocrinol Investiga. 2016;39(5):577-83.
  4. Godfrey KM, Barker DJ. Fetal programming and adult health. Public Health Nutrition. 2001;4(2B):611-624.
  5. Bitó T, Földesi I, Nyári T, Pál A. Prediction of gestational diabetes mellitus in a high‐risk group by insulin measurement in early pregnancy. Diabet Med. 2005;22(10):1434-9.
  6. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol.2018;131(2):e49-e64.
  7. Solomon CG, Willett WC, Carey VJ, Rich-Edwards J, Hunter DJ, Colditz GA, et al. A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA. 1997;278(13):1078-83.
  8. Kiani F, Naz MSG, Sayehmiri F, Sayehmiri K, Zali H. The risk factors of gestational diabetes mellitus: a systematic review and meta-analysis study. Diabetes. 2017;10:17-263.
  9. Kim C, Liu T, Valdez R, Beckles GL. Does frank diabetes in first-degree relatives of a pregnant woman affect the likelihood of her developing gestational diabetes mellitus or nongestational diabetes? Am J Obstet Gynecol. 2009;201(6):576-e1.
  10. Hedderson MM, Williams MA, Holt VL, Weiss NS, Ferrara A. Body mass index and weight gain prior to pregnancy and risk of gestational diabetes mellitus. Am J Obstet Gynecol. 2008;198(4):409-e1.
  11. Hedderson MM, Gunderson EP, Ferrara A. Gestational weight gain and risk of gestational diabetes mellitus. Obstet Gynecol. 2010;115(3):597-604.
  12. Gibson KS, Waters TP, Catalano PM. Maternal weight gain in women who develop gestational diabetes mellitus. Obstet Gynecol. 2012;119(3):560-5.
  13. Carreno CA, Clifton RG, Hauth JC, Myatt L, Roberts JM, Spong CY,   Varner MW,  Thorp Jr JM,  Mercer BM,  Peaceman AM, Ramin SM, W, Sciscione A, Tolosa JE, Saade GR, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Excessive early gestational weight gain and risk of gestational diabetes mellitus in nulliparous women. Obstet Gynecol. 2012;119(6):1227-33.
  14. Miller C, Lim E. The risk of diabetes after giving birth to a macrosomic infant: data from the NHANES cohort. Matern Health, Neonatol Perinatol. 2021;7(1):12.
  15. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-S42.
  16. ACOG Practice Bulletin No. 190 Summary: Gestational Diabetes Mellitus. Obstet Gynecol. 2018;131(2):406-408.
  17. Temming, LA, Tuuli MG., Stout MJ, Macones GA, Cahill AG. Diagnostic ability of elevated 1-h glucose challenge test. J Perinatol. 2016;36(5):342-6.
  18. Metzger BE, Gabbe SG, Persson B, Lowe LP, Dyer AR, Oats JJ., Buchanan TA. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy: response to Weinert. Diabetes Care. 2010;33(7):e98-e98.
  19. Harper LM, Jauk V, Longo S, Biggio JR, Szychowski JM, Tita AT. Early gestational diabetes screening in obese women: a randomized controlled trial. Am J Obstet Gynecol. 2020;222(5):495-e1.
  20. Nethery E, Law MR, Kotaska A, Janssen PA, Hutcheon JA. The effect of changing screening practices and demographics on the incidence of gestational diabetes in British Columbia, 2005–2019. CMAJ. 2023;195(11):E396-E403.
  21. Ozcimen EE, Uckuyu A, Ciftci FC, Yanik FF, Bakar C. Diagnosis of gestational diabetes mellitus by use of the homeostasis model assessment–insulin resistance index in the first trimester. Gynecol Endocrinol. 2008;24(4):224-9.
  22. Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obstet Gynecol. 1991;165(6):1667-72.
  23. Buchanan TA, Watanabe RM, Xiang AH. Limitations in surrogate measures of insulin resistance.  J Clin Endocrinol Metabol. 2010;95(11):4874-6.
  24. Tritos NA, Mantzoros CS. Syndromes of severe insulin resistance. J Clin Endocrinol Metabol. 1998;83(9):3025-30.
  25. Grewal E, Kansara S, Kachhawa G, et al. Prediction of gestational diabetes mellitus at 24 to 28 weeks of gestation by using first-trimester insulin sensitivity indices in Asian Indian subjects. Metabolism. 2012;61(5):715-20.
  26. Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First trimester maternal serum screening using biochemical markers PAPP-A and free β-hCG for down syndrome, patau syndrome and edward syndrome. Indian J Clin Biochem. 2013;28(1):3-12.
  27. Farina A, Rapacchia G, Freni Sterrantino A, Pula G, Morano D, Rizzo N. Pro­spective evaluation of ultrasound and biochemical‐based multivariable models for the prediction of late pre‐eclampsia. Prenatal Diag. 2011;31(12):1147-52.
  28. Zhong Y, Zhu F, Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. BMC Pregnancy Childbirth. 2015;15(1):191.
  29. Beneventi F, Simonetta M, Lovati E, Albonico G, Tinelli C, Locatelli E, Spinillo A. First trimester pregnancy‐associated plasma protein‐A in pregnancies com­plicated by subsequent gestational diabetes. Prenatal Diag. 2011;31(6):523-8.
  30. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. 
  31. J Clin Endocrinol Metabol. 2002;87(4):1762-67.
  32. Sun IY, Overgaard MT, Oxvig C, Giudice LC. Pregnancy-associated plasma protein A proteolytic activity is associated with the human placental trophoblast cell membrane. J Clin Endocrinol Metabol. 2002;87(11):5235-40.
  33. Talasaz ZH, Sadeghi R, Askari F, Dadgar S, Vatanchi A. First trimesters pregnancy-associated plasma protein-a levels value to predict gestational diabetes mellitus: a systematic review and meta-analysis of the literature. Taiwanese J Obstet Gynecol. 2018;57(2):181-9.

Articole din ediţiile anterioare

OBSTETRICS | Ediţia 1 43 / 2024

Lobar holoprosencephaly associated with maternal diabetes mellitus – case report

Diana Ioana Voicu, Monica Mihaela Cîrstoiu

The term holoprosencephaly (HPE) describes a spectrum of cerebral and facial malformations that result from an absent or incomplete division of emb...

28 martie 2024
GYNECOLOGY | Ediţia 1 27 / 2020

Biomarkeri în endometrioză

Alexandra Bouariu, Corina Gică, George Iancu, Radu Botezatu, Gheorghe Peltecu

Endometrioza reprezintă o boală debilitantă, estimându-se a afecta 10% dintre femeile la vârstă reproductivă. En­do­me­trio­za se caracterizează pr...

13 martie 2020
OBSTRETICS | Ediţia 1 39 / 2023

The metabolic pattern for monitoring and management of gestational diabetes

Cristina Oana Daciana Teodorescu, Gabriel-Petre Gorecki, Liana Pleș, Romina-Marina Sima, Denisa-Oana Bălălău, Alexandru Filipescu, Andrei Teodorescu

Globally, the prevalence rate of overweight or obesity between 1980 and 2013 increased by 27.5% for adults and by 47.1% for children, to a total of...

30 martie 2023
NEONATOLOGY | Ediţia 4 38 / 2022

Dificultăţi în managementul hiperglicemiei la nou-născuţii cu greutate extrem de mică la naştere – prezentare de caz

Diana Iulia Vasilescu, Adriana Mihaela Dan, Laura Andreea Ştefan, Monica Mihaela Cîrstoiu

Hyperglycemia can be a severe complication in the first weeks of life for 60-80% of extremely low birth weight (ELBW) infants, and it has been asso...

30 noiembrie 2022